NO20082093L - Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser - Google Patents
Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaserInfo
- Publication number
- NO20082093L NO20082093L NO20082093A NO20082093A NO20082093L NO 20082093 L NO20082093 L NO 20082093L NO 20082093 A NO20082093 A NO 20082093A NO 20082093 A NO20082093 A NO 20082093A NO 20082093 L NO20082093 L NO 20082093L
- Authority
- NO
- Norway
- Prior art keywords
- protein kinases
- pyrazole
- inhibition
- pyrimidine derivatives
- kinase
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title abstract 3
- 108060006633 protein kinase Proteins 0.000 title abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72415805P | 2005-10-06 | 2005-10-06 | |
PCT/US2006/038917 WO2007044441A2 (en) | 2005-10-06 | 2006-10-04 | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082093L true NO20082093L (no) | 2008-07-03 |
Family
ID=37943366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082093A NO20082093L (no) | 2005-10-06 | 2008-05-05 | Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser |
Country Status (11)
Country | Link |
---|---|
US (2) | US20070082900A1 (zh) |
EP (1) | EP1942900B1 (zh) |
JP (3) | JP5152922B2 (zh) |
CN (1) | CN101360499B (zh) |
BR (1) | BRPI0616985B1 (zh) |
CA (1) | CA2627623C (zh) |
NO (1) | NO20082093L (zh) |
NZ (1) | NZ567151A (zh) |
TW (1) | TWI421078B (zh) |
WO (1) | WO2007044441A2 (zh) |
ZA (1) | ZA200802998B (zh) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
JP2009515882A (ja) * | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | プロテインキナーゼを阻害するための方法 |
CA2643362A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
RU2008150419A (ru) * | 2006-05-22 | 2010-09-20 | Шеринг Корпорейшн (US) | ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ CDK |
US20100143332A1 (en) * | 2006-11-17 | 2010-06-10 | Schering Corporation | Combination therapy for proliferative disorders |
EP2409700A1 (en) | 2007-05-08 | 2012-01-25 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
EP2155725A1 (en) * | 2007-06-07 | 2010-02-24 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
WO2009061781A1 (en) * | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
CN101959887B (zh) | 2008-01-08 | 2013-07-31 | 阵列生物制药公司 | 作为激酶抑制剂的吡咯并吡啶 |
WO2009089359A1 (en) * | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
JP5530422B2 (ja) * | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのgem−二置換およびスピロ環式アミノピリジン/ピリミジン |
CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
SI3372605T1 (sl) * | 2008-10-22 | 2022-03-31 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-a)pirimidinske spojine kot zaviralci TRK-kinaze |
CN102271515B (zh) * | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
CN102317291B (zh) * | 2009-02-13 | 2015-02-11 | 拜耳知识产权有限责任公司 | 稠合嘧啶 |
WO2010118207A1 (en) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
BR112012005550A2 (pt) * | 2009-09-11 | 2015-09-08 | Cylene Pharmaceuticals Inc | lactamas heterociclo-substituídas farmaceuticamente úteis |
NZ601325A (en) | 2010-01-05 | 2014-09-26 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
NZ601324A (en) * | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
EP3521291A1 (en) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
CA2830516C (en) | 2011-03-23 | 2017-01-24 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2755482B1 (en) | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
JP6377068B2 (ja) * | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP6095857B2 (ja) * | 2013-11-15 | 2017-03-15 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
KR102153886B1 (ko) | 2013-12-06 | 2020-09-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제 억제제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물, 이의 제조 방법, 이의 상이한 고체형 및 방사성표지된 유도체 |
JP2017501145A (ja) | 2013-12-23 | 2017-01-12 | ノージン ビーブイ | Ccr9調節因子として有用な化合物 |
GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
PT3152212T (pt) | 2014-06-05 | 2020-03-13 | Vertex Pharma | Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo |
RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
MX2017006412A (es) | 2014-11-16 | 2017-09-12 | Array Biopharma Inc | Forma cristalina de sulfato acido de (s)-n-(5-((r)-2-(2,5-difluoro fenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxi pirrolidina-1-carboxamida. |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
GB201517263D0 (en) * | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
KR20180054657A (ko) | 2015-09-30 | 2018-05-24 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제 및 atr 저해제의 병용물을 사용한 암 치료 방법 |
JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. | Trk阻害薬耐性がんにおける点変異およびそれに関連する方法 |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MX2018012163A (es) | 2016-04-04 | 2019-07-08 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirr olidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina- 1-carboxamida. |
RS61463B1 (sr) | 2016-05-18 | 2021-03-31 | Loxo Oncology Inc | Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
AR110252A1 (es) * | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
SG11202000714QA (en) | 2017-07-28 | 2020-02-27 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
CN113271940A (zh) * | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
JP7385658B2 (ja) | 2018-10-30 | 2023-11-22 | クロノス バイオ インコーポレイテッド | Cdk9活性を調節するための化合物、組成物、および方法 |
TW202033526A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商貝達藥業股份有限公司 | 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途 |
CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
WO2021092246A1 (en) * | 2019-11-08 | 2021-05-14 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
CR20220308A (es) | 2019-11-25 | 2022-08-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0438730Y2 (zh) * | 1986-03-26 | 1992-09-10 | ||
JP3039751U (ja) * | 1996-12-09 | 1997-07-31 | 尚子 小園 | 鞄類用補助具 |
JP2002295682A (ja) * | 2001-03-28 | 2002-10-09 | Yazaki Corp | 防水構造およびこの防水構造に用いられる座金部材 |
AU2003240488A1 (en) * | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196092B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
KR101088922B1 (ko) * | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
US7601724B2 (en) * | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AR041134A1 (es) * | 2002-09-04 | 2005-05-04 | Schering Corp | Pirazolopirimidinas como inhibidores de la quinasa dependiente de ciclina |
JP4564485B2 (ja) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ[1,5−a]ピリミジン誘導体 |
EP1608652A1 (en) * | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
JP3940700B2 (ja) * | 2003-05-22 | 2007-07-04 | 茂 相馬 | 楽器用ケース |
PE20051089A1 (es) * | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
JP3104094U (ja) * | 2004-03-18 | 2004-09-02 | チャン ホアン−リン | 両用スーツケース |
TW200745123A (en) * | 2005-10-06 | 2007-12-16 | Schering Corp | Pyrazolopyrimidines as protein kinase inhibitors |
CA2624826A1 (en) * | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
JP3174645U (ja) * | 2012-01-19 | 2012-03-29 | 株式会社セイバン | ランドセル |
-
2006
- 2006-10-04 CN CN200680045935.5A patent/CN101360499B/zh active Active
- 2006-10-04 NZ NZ567151A patent/NZ567151A/en not_active IP Right Cessation
- 2006-10-04 BR BRPI0616985-6A patent/BRPI0616985B1/pt active IP Right Grant
- 2006-10-04 CA CA2627623A patent/CA2627623C/en active Active
- 2006-10-04 US US11/542,801 patent/US20070082900A1/en not_active Abandoned
- 2006-10-04 WO PCT/US2006/038917 patent/WO2007044441A2/en active Application Filing
- 2006-10-04 EP EP06836185.6A patent/EP1942900B1/en active Active
- 2006-10-04 TW TW095136818A patent/TWI421078B/zh not_active IP Right Cessation
- 2006-10-04 JP JP2008534673A patent/JP5152922B2/ja active Active
-
2008
- 2008-04-04 ZA ZA200802998A patent/ZA200802998B/xx unknown
- 2008-05-05 NO NO20082093A patent/NO20082093L/no not_active Application Discontinuation
-
2010
- 2010-01-15 US US12/688,664 patent/US8211854B2/en active Active
-
2012
- 2012-01-27 JP JP2012015831A patent/JP5520325B2/ja active Active
-
2014
- 2014-01-09 JP JP2014002164A patent/JP2014062129A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20070082900A1 (en) | 2007-04-12 |
CN101360499A (zh) | 2009-02-04 |
WO2007044441A2 (en) | 2007-04-19 |
TWI421078B (zh) | 2014-01-01 |
JP5520325B2 (ja) | 2014-06-11 |
AU2006302435A1 (en) | 2007-04-19 |
CA2627623C (en) | 2014-04-22 |
US8211854B2 (en) | 2012-07-03 |
JP5152922B2 (ja) | 2013-02-27 |
TW200800218A (en) | 2008-01-01 |
BRPI0616985A2 (pt) | 2009-08-04 |
JP2012082234A (ja) | 2012-04-26 |
WO2007044441A3 (en) | 2007-07-26 |
JP2014062129A (ja) | 2014-04-10 |
EP1942900A2 (en) | 2008-07-16 |
EP1942900B1 (en) | 2015-06-03 |
CN101360499B (zh) | 2015-10-07 |
JP2009511486A (ja) | 2009-03-19 |
NZ567151A (en) | 2012-03-30 |
BRPI0616985B1 (pt) | 2021-10-26 |
ZA200802998B (en) | 2009-10-28 |
CA2627623A1 (en) | 2007-04-19 |
US20100125068A1 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082093L (no) | Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser | |
MXPA06010904A (es) | Inhibidores de pirazol cinasa triciclicos. | |
NO20082091L (no) | Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer | |
NO20082092L (no) | Pyrazolopyrimidiner som proteinkinaseinhibitorer | |
NO20072795L (no) | Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser | |
DE602007013441D1 (de) | Pyrazolopyrimidine als pi3k-lipidkinasehemmer | |
NO20064046L (no) | Pyrazolpyrimidinderivater som syklinavhengige kinaseinhibitorer | |
MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
WO2007079164A3 (en) | Protein kinase inhibitors | |
WO2006124354A3 (en) | Tyrosine kinase inhibitors | |
GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
WO2007041358A8 (en) | Substituted pyrazole compounds | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
MX2009003734A (es) | Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina. | |
HK1112233A1 (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer | |
MX2010006203A (es) | Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina. | |
TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
GEP20125368B (en) | Kinase inhibitors | |
MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
MX2009003733A (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. | |
WO2007113212A3 (en) | Use of a kinase inhibitor for the treatment of particular resistant tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP, US Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |